We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 20, 2021

Addition of Apalutamide vs Placebo to Abiraterone and Prednisone for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol 2021 Sep 30;[EPub Ahead of Print], F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, S Oudard, T Steuber, H Suzuki, D Wu, K Yeruva, P De Porre, S Brookman-May, S Li, J Li, S Thomas, KB Bevans, SD Mundle, SA McCarthy, DE Rathkopf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading